Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 11820 for:    Oral Cancer

Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03682562
Recruitment Status : Not yet recruiting
First Posted : September 24, 2018
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Noha Adel Azab, Cairo University

Brief Summary:
This study aims to identify the accuracy of DNA integrity index in differentiating between oral premalignant lesions and oral cancer.

Condition or disease Intervention/treatment
Oral Cancer Oral Lichen Planus Oral Leukoplakia Diagnostic Test: DNA Integrity Index

Detailed Description:

As stated by the U.S. Preventive Services Task Force and the National Institute of Dental and Craniofacial Research, the main screening test for oral cancer remains conventional oral examination of the oral cavity. Most cases of oral cancer are preceded by a clinically visible lesion. These lesions are called oral potentially malignant disorders. These are leukoplakia, erythroplakia, oral submucous fibrosis, oral lichen planus and discoid lupus erythematosis. Leukoplakia has a reported annual transformation rate of 2-3%, while OLP has a rate of 0.5% .

Full thickness tissue biopsy is the "gold standard" for diagnosing suspicious lesions should they be encountered during COE. However, oral biopsy is an invasive technique that can be challenging in sites as the floor of the mouth or the soft palate . The invasive nature of a biopsy also makes it unsuitable for cancer screening in high-risk populations.

Thus there is a need for a diagnostic aid that can help primary care providers determine which patients need to be biopsied or referred to a specialist.

Nucleic acids can be released actively or passively into the circulation by both living and dead cells, where the latter is considered the predominant source. Programmed cell death gives neatly digested DNA fragments of approximately 180 bp in length. In case of solid tumors, cell-free DNA is released through necrosis which generates longer DNA fragments due to haphazard and incomplete digestion of DNA. Thus, the integrity of the DNA fragment can determine its origin making DNA integrity a potential marker for oral cancer.

The DNA integrity index (DII) is the ratio between the longer DNA fragments to the shorter ones. A higher index has been reported in breast, prostate, liver and cervical cancer. Jiang et al. 2006 found that the DNA integrity index was significantly higher in oral cancer patients than in normal ones and reported a sensitivity and specificity values of 84.5% 83% respectively . The next step for such a marker would be early quantification of performance in clinical settings to determine if it is possible to extrapolate cut off values.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 90 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Estimated Study Start Date : March 15, 2019
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : September 2019


Group/Cohort Intervention/treatment
Oral Cancer
Patients diagnosed clinically and histopathologically as having oral cancer.
Diagnostic Test: DNA Integrity Index

This test will be performed for ALL three groups:

Sample collection:

Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.

DNA integrity analysis:

The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.


Premalignant Oral Lesions
Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
Diagnostic Test: DNA Integrity Index

This test will be performed for ALL three groups:

Sample collection:

Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.

DNA integrity analysis:

The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.


Normal Subjects

Patients who give a history of:

  • No smoking
  • No alcohol
  • No systemic disease; and who on conventional oral examination have:
  • No visible oral lesions on conventional oral examination .
  • Good oral hygiene.
Diagnostic Test: DNA Integrity Index

This test will be performed for ALL three groups:

Sample collection:

Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.

DNA integrity analysis:

The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones.





Primary Outcome Measures :
  1. Difference in DNA Integrity Index [ Time Frame: 1 month after the end of patient recruitment ]
    The DNA integrity will be compared between the three group to determine whether there is a difference between them in that aspect or not


Biospecimen Retention:   Samples With DNA
Salivary Samples will be obtained for DNA extraction, Biosamples will be stored in -80 degrees after patient's consent


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population

Group I: (Clinical examination and Biopsy) Patients diagnosed clinically and histopathologically as having oral cancer. Group II: (History and Clinical examination)

Patients who give a history of:

  • No smoking
  • No alcohol
  • No systemic disease; and who on conventional oral examination(National Institute of Dental and Craniofacial Research, 2013b) have:
  • No visible oral lesions on conventional oral examination .
  • Good oral hygiene. Group III: (Clinical examination and Biopsy) Patients diagnosed clinically and histopathologically with oral lichen planus as stated by modified WHO criteria (van der Meij and van der Waal, 2003).
Criteria

Patients in this study will be divided into three groups:

Group I: Patients diagnosed histopathologically with oral cancer recruited from the National Cancer Institute, who have yet to receive treatment.

Group II: Healthy Controls

Inclusion Criteria:

  • No visible oral lesions as detected by conventional oral examination
  • Good oral hygiene, with healthy gingival tissues
  • Non-smokers
  • No systemic disease Group III: Patients diagnosed with oral lichen planus according to the modified WHO (van der Meij and van der Waal, 2003)diagnostic criteria not receiving treatment at least 8 weeks prior to enrollment.

Layout table for additonal information
Responsible Party: Noha Adel Azab, Researcher, Cairo University
ClinicalTrials.gov Identifier: NCT03682562     History of Changes
Other Study ID Numbers: N1P1H1D1
First Posted: September 24, 2018    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: According to the mode of data entry, if it is solely numerical it can be more easily shared and deposited on repositories, however patient clinical photos may not be possible to share

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Mouth Neoplasms
Lichen Planus, Oral
Leukoplakia, Oral
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Mouth Diseases
Lichen Planus
Precancerous Conditions
Leukoplakia
Stomatognathic Diseases
Lichenoid Eruptions
Skin Diseases, Papulosquamous
Skin Diseases
Pathological Conditions, Anatomical